Improved Prognosis and CET Benefit Prediction with RSClinN+ in Breast Cancer
The following is a summary of “Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer,” published in the December 20 ...
